Molecular Partners Publishes MP0317 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Molecular Partners announced the publication of Phase 1 clinical data in Nature Cancer demonstrating the potential of the tumor-localized CD40 agonist, MP0317, to modulate the tumor microenvironment. MP0317 is designed to activate immune cells specifically within the TME by anchoring to fibroblast activation protein, which is expressed in high amounts in the stroma of various solid tumors. This tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. The peer-reviewed paper published by Steehgs et al., entitled "Tumor-localized CD40 agonism with MP0317, a FAPxCD40 DARPin, reprograms the tumor microenvironment - results of a Phase 1 monotherapy study", reports the positive results from the completed Phase 1 dose escalation study of MP0317. The comprehensive biomarker data confirm proof-of-mechanism for MP0317, including tumor-localized activation of the CD40 pathway and evidence of TME remodeling in patients with advanced solid tumors. MP0317 displayed a favorable safety profile up to the highest tested dose and serum pharmacokinetics confirmed suitability for dosing either weekly or every three weeks. Of the 46 patients in the study, one patient achieved an unconfirmed partial response and 14 patients stable disease in this heterogeneous population with advanced diseases. Data were presented at the 2024 Annual Meetings of the American Society of Clinical Oncology and of the Society for Immunotherapy of Cancer.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.000
Low
8.00
Averages
10.00
High
12.00
Current: 4.000
Low
8.00
Averages
10.00
High
12.00
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Molecular Partners Updates on Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners' MP0712 is currently undergoing a US multicenter Phase 1/2a clinical trial with initial patient dosing ongoing, and preliminary data is expected in the coming months, while comprehensive safety and efficacy data is anticipated in 2027, indicating the company's potential in treating small cell lung cancer.
- Compassionate Use Program: The Nuclear Medicine Research Institute in South Africa has initiated a compassionate use program utilizing a DLL3-targeted Radio-DARPin with 225Ac, highlighting the versatility of DARPins as isotope-agnostic vectors and expanding the company's applications in cancer treatment.
- New Candidate Plans: Molecular Partners plans to initiate first-in-human imaging for MP0726 targeting MSLN in H2 2026 and aims to submit two INDs in 2027, demonstrating the company's ongoing innovation in targeted cancer therapeutics.
- Strengthened Partnerships: The strategic collaboration with Orano Med continues to deepen, leveraging the advantages of isotopes like 212Pb and 225Ac to advance Radio-DARPin therapies, aiming to address unmet medical needs and enhance patient treatment outcomes.
See More
Molecular Partners Updates on DARPin Therapeutics Pipeline
- Clinical Trial Progress: Molecular Partners is currently dosing patients in the first cohort of its US multicenter Phase 1/2a study for MP0712, with five sites now open and recruiting, potentially offering new treatment options for patients with small cell lung cancer and other neuroendocrine cancers.
- Data Release Expectations: The company anticipates initial data from the MP0712 study within the next few months, while a more comprehensive dataset on safety and efficacy is expected in 2027, which will provide critical clinical results that could influence future financing and partnership opportunities.
- New Drug Development Plans: Molecular Partners plans to advance MP0726 towards first-in-human imaging in the second half of 2026 and expects to file two INDs for its targeted cancer therapeutics in 2027, indicating ongoing innovation and development in cancer treatment.
- Strong Financial Position: As of March 31, 2026, the company reported cash and cash equivalents totaling CHF 79 million (approximately $100 million), which is expected to fund its operations and capital requirements into late 2027, demonstrating robust financial management.
See More
Molecular Partners Administers Initial Doses of Radiopharmaceutical
- Initial Administration: Molecular Partners (MOLN) announced on Thursday that it has administered the initial doses of its radiopharmaceutical, marking a significant milestone in its development process, although specific dosage numbers and patient feedback have not been disclosed.
- R&D Progress: The administered radiopharmaceutical is a key product in the company's oncology treatment portfolio, expected to positively impact future clinical trials and market launch, despite the current lack of detailed clinical data.
- Market Potential: The development of radiopharmaceuticals aligns with the growing demand for innovative cancer treatment options, potentially providing the company with new revenue streams, although it faces intense market competition and regulatory challenges.
- Strategic Importance: This administration not only showcases Molecular Partners' technical capabilities in biopharmaceuticals but may also attract investor interest, enhancing the company's standing in the biopharma industry.
See More
Molecular Partners and Orano Med Initiate DLL3-Targeting Therapy Clinical Trial
- Clinical Trial Launch: Molecular Partners and Orano Med have initiated a clinical trial for DLL3-targeting MP0712 in the US, with the first patient dosed, marking a critical step in the development of this therapy aimed at providing new treatment options for small cell lung cancer patients.
- Targeting Mechanism: MP0712 targets the tumor-associated protein DLL3, utilizing 212Pb as a therapeutic payload, with DLL3 expressed in over 85% of small cell lung cancer tumors, highlighting its significance in enhancing treatment efficacy.
- Data Release Timeline: Initial data is expected to be reported in 2026, while comprehensive efficacy data is anticipated in 2027, which will provide crucial insights for future clinical applications and may drive the development of additional Radio-DARPin candidates.
- Multicenter Recruitment: Currently, five centers in the US are actively recruiting patients using a
See More
Molecular Partners Initiates DLL3-Targeting Therapy Study
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a study of MP0712 at five centers in the US, marking a significant advancement in DLL3-targeted therapy that could offer new treatment options for small cell lung cancer patients.
- Dose Escalation Study: As the first Radio-DARPin candidate, MP0712 is undergoing a dose escalation study with up to four levels, and the first patient has entered repeat dosing, with initial data expected in 2026 to further validate its clinical safety profile.
- Targeted Therapy Potential: DLL3 is expressed in over 85% of small cell lung cancer tumors, and the development of MP0712 aims to leverage its high expression in tumors to provide treatment options for various aggressive neuroendocrine tumors, indicating significant market potential.
- Future Data Outlook: Initial data is anticipated within the coming months, while comprehensive safety and efficacy data is expected in 2027, laying the groundwork for the development of subsequent Radio-DARPin candidates.
See More
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
Molecular Partners Updates on Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners' MP0712 is currently undergoing a US multicenter Phase 1/2a clinical trial with initial patient dosing ongoing, and preliminary data is expected in the coming months, while comprehensive safety and efficacy data is anticipated in 2027, indicating the company's potential in treating small cell lung cancer.
- Compassionate Use Program: The Nuclear Medicine Research Institute in South Africa has initiated a compassionate use program utilizing a DLL3-targeted Radio-DARPin with 225Ac, highlighting the versatility of DARPins as isotope-agnostic vectors and expanding the company's applications in cancer treatment.
- New Candidate Plans: Molecular Partners plans to initiate first-in-human imaging for MP0726 targeting MSLN in H2 2026 and aims to submit two INDs in 2027, demonstrating the company's ongoing innovation in targeted cancer therapeutics.
- Strengthened Partnerships: The strategic collaboration with Orano Med continues to deepen, leveraging the advantages of isotopes like 212Pb and 225Ac to advance Radio-DARPin therapies, aiming to address unmet medical needs and enhance patient treatment outcomes.
See More
Molecular Partners Updates on DARPin Therapeutics Pipeline
- Clinical Trial Progress: Molecular Partners is currently dosing patients in the first cohort of its US multicenter Phase 1/2a study for MP0712, with five sites now open and recruiting, potentially offering new treatment options for patients with small cell lung cancer and other neuroendocrine cancers.
- Data Release Expectations: The company anticipates initial data from the MP0712 study within the next few months, while a more comprehensive dataset on safety and efficacy is expected in 2027, which will provide critical clinical results that could influence future financing and partnership opportunities.
- New Drug Development Plans: Molecular Partners plans to advance MP0726 towards first-in-human imaging in the second half of 2026 and expects to file two INDs for its targeted cancer therapeutics in 2027, indicating ongoing innovation and development in cancer treatment.
- Strong Financial Position: As of March 31, 2026, the company reported cash and cash equivalents totaling CHF 79 million (approximately $100 million), which is expected to fund its operations and capital requirements into late 2027, demonstrating robust financial management.
See More
Molecular Partners Administers Initial Doses of Radiopharmaceutical
- Initial Administration: Molecular Partners (MOLN) announced on Thursday that it has administered the initial doses of its radiopharmaceutical, marking a significant milestone in its development process, although specific dosage numbers and patient feedback have not been disclosed.
- R&D Progress: The administered radiopharmaceutical is a key product in the company's oncology treatment portfolio, expected to positively impact future clinical trials and market launch, despite the current lack of detailed clinical data.
- Market Potential: The development of radiopharmaceuticals aligns with the growing demand for innovative cancer treatment options, potentially providing the company with new revenue streams, although it faces intense market competition and regulatory challenges.
- Strategic Importance: This administration not only showcases Molecular Partners' technical capabilities in biopharmaceuticals but may also attract investor interest, enhancing the company's standing in the biopharma industry.
See More
Molecular Partners and Orano Med Initiate DLL3-Targeting Therapy Clinical Trial
- Clinical Trial Launch: Molecular Partners and Orano Med have initiated a clinical trial for DLL3-targeting MP0712 in the US, with the first patient dosed, marking a critical step in the development of this therapy aimed at providing new treatment options for small cell lung cancer patients.
- Targeting Mechanism: MP0712 targets the tumor-associated protein DLL3, utilizing 212Pb as a therapeutic payload, with DLL3 expressed in over 85% of small cell lung cancer tumors, highlighting its significance in enhancing treatment efficacy.
- Data Release Timeline: Initial data is expected to be reported in 2026, while comprehensive efficacy data is anticipated in 2027, which will provide crucial insights for future clinical applications and may drive the development of additional Radio-DARPin candidates.
- Multicenter Recruitment: Currently, five centers in the US are actively recruiting patients using a
See More
Molecular Partners Initiates DLL3-Targeting Therapy Study
- Clinical Trial Launch: Molecular Partners, in collaboration with Orano Med, has initiated a Phase 1/2a study of MP0712 at five centers in the US, marking a significant advancement in DLL3-targeted therapy that could offer new treatment options for small cell lung cancer patients.
- Dose Escalation Study: As the first Radio-DARPin candidate, MP0712 is undergoing a dose escalation study with up to four levels, and the first patient has entered repeat dosing, with initial data expected in 2026 to further validate its clinical safety profile.
- Targeted Therapy Potential: DLL3 is expressed in over 85% of small cell lung cancer tumors, and the development of MP0712 aims to leverage its high expression in tumors to provide treatment options for various aggressive neuroendocrine tumors, indicating significant market potential.
- Future Data Outlook: Initial data is anticipated within the coming months, while comprehensive safety and efficacy data is expected in 2027, laying the groundwork for the development of subsequent Radio-DARPin candidates.
See More
Molecular Partners Announces Clinical Trial Progress
- Clinical Trial Progress: Molecular Partners will present the clinical trial progress of its MP0712 for small cell lung cancer at the 2026 American Society of Clinical Oncology Annual Meeting, indicating the company's ongoing innovation in cancer treatment.
- Targeted Therapy Candidate: MP0712 is a 212Pb-based Radio-DARPin therapy targeting DLL3, which is expressed in over 85% of small cell lung cancer tumors, showcasing its potential to provide new treatment options for patients.
- Multicenter Study Recruitment: The US multicenter Phase 1/2a study of MP0712 is actively recruiting patients to assess safety and determine a recommended Phase 2 dose, with initial clinical data expected to be shared in 2026, further advancing product development.
- International Collaboration: The strategic partnership with Orano Med combines expertise to accelerate the clinical development of MP0712, reflecting the company's leadership and market potential in the field of radiopharmaceutical therapy.
See More
